|
Suicide rating’ could be given to every new drug licensed in UK
Every new drug licensed in Britain will be given a "suicide rating" under proposals for a big shake-up in the rules governing pharmaceutical development. European regulators are also to require pharmaceutical companies to include a comprehensive suicide assessment into trials of new medicines. The reform, based on a system adopted recently in the United States, has been fuelled by a growing body of evidence that drugs that affect the brain can heavily influence behaviour through seemingly innocuous changes in body chemistry. Medicines to treat acne, swelling, heartburn, pain, obesity, high blood pressure and cholesterol, bacterial infections, smoking and insomnia have all been associated recently with psychiatric problems. There have been warnings about the potential side-effects of Acomplia, an antiobesity drug, Roaccutane, an acne treatment, and Champix, an antismoking medication, which together have been prescribed to more than 60,000 patients in Britain.
No bribes, says DA
No bribes, says DA Annestacia rape case postponed Man's body found in cattle-feed mixer Wife allegedly stabs husband Gugulethu girl found ID dismisses Zille's claims ANC MP kicked off SAA flight: report Spy scandal: Rasool capitulates New info on Mzoli kidnapping case Missing mom contacts cops .
Have you heard the one about the Alexandrian police band ...
Indeed, and justifiably so when you consider that she's a professional TV-serial writer herself. Her previous works include Wagh El-Qamar (Face of the Moon), starring screen legend Faten Hamama and Shams Youm Gedid (The Sun of a New Day) starring Nelly Karim, among numerous other small screen classics. .
Dermatologist's family to French: Suspect mocking your laws
The widow of slain Loop dermatologist David Cornbleet broke down in tears during an emotional meeting Monday with French officials who are holding her husband's suspected killer on an island in the French West Indies. Aileen Cornbleet's family also was told that Hans Peterson, in a statement to French authorities, said he had traveled to St. Martin to surrender because he wanted to avoid the U.S. justice system, said her son, Jon Cornbleet. "He basically is laughing at our system and their system,'' said Cornbleet, who had to walk out of the meeting at one point. "It makes me sick to my stomach.'' The French authorities are here to talk to the Chicago prosecutors and detectives who investigated Peterson, a 29-year-old man who surrendered to authorities last August in French-controlled St.
New Year, New Cars, New Drivers And Junior Is Back!
Dale Earnhardt Jr. was the story of the second half of last year's season and most of the off season what with not winning a race since 2006, his public split with DEI, and subsequent signing with Hendrick Motorsports. Take that Teresa! Junior drove a great race and demonstrated again his prowess at the superspeedways like Daytona and Talladega. He ran up front most of the night, his team executed a flawless pit stop which brought him out in second in the 50 lap finale, and he ran clean and hard with teammates and competitors alike. It was amazing to see Junior, JJ, and Jeff Gordon freight training the high line and keeping Earnhardt at the front. The race had it's rough moments with a mini-big one in the 50 lap second segment which sidelined four cars (Truex, McMurray, Gilland, and Biffle).
Data Demonstrate that Obagi Medical Products' Condition & Enhance Skin ...
SAN ANTONIO, Feb. 1 /PRNewswire-FirstCall/ -- Obagi Medical Products, Inc. (NASDAQ: OMPI) , a leader in topical aesthetic and therapeutic skin health systems, announced the results of a wide-ranging investigator assessment study on the effects of its Condition & Enhance System on facial rejuvenation procedures today at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio. The data show that the unique 4% hydroquinone- based system in combination with common non-surgical and surgical facial rejuvenation procedures improved overall skin quality in up to 80 percent of subjects. As rated by investigators, eighty-three percent of patients treated with the Condition & Enhance System and botulinum toxin type A injections (i.e., Botox(R)) experienced a 1-grade improvement (from moderate to mild or mild to none) in hyperpigmentation.
|
